¿¬¼ö°­ÁÂ
¸¸¼ºÄáÆϺ´ ¹Ì³×¶ö-»ÀÁúȯ ¿¬±¸È¸ CKD-MBD ¿¬±¸È¸ ¿¬¼ö°­Á : 2023-09-10

¸¸¼ºÄáÆϺ´ ¹Ì³×¶ö-»ÀÁúȯ ¿¬±¸È¸ CKD-MBD ¿¬±¸È¸ ¿¬¼ö°­Á : 2023-09-10
±³À°ÀÏÀÚ : 2023-09-10
±³À°Àå¼Ò : ¼­¿ï/°í·Á´ëÇб³ ±¸·Îº´¿ø »õ·Ò ±³À°°ü 1Ãþ ´ë°­´ç

±³À°ÁÖÁ¦ : CKD-MBD ¿¬±¸È¸ ¿¬¼ö°­ÁÂ

ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸¸¼ºÄáÆϺ´ ¹Ì³×¶ö-»ÀÁúȯ ¿¬±¸È¸

´ã´çÀÚ : ´ëÇѽÅÀåÇÐȸ
¿¬¶ôó : 02-3486-8736

À̸ÞÀÏ : ksn@ksn.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 250¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 40,000¿ø  

ºñ°í Àü¹®ÀÇ 3¸¸¿ø, ÀüÀÓÀÇ ¹× Àü°øÀÇ 2¸¸¿ø, °£È£»ç 1¸¸¿ø, ´çÀϵî·Ï : Àü¹®ÀÇ 4¸¸¿ø, ±×¿Ü 3¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 08:30~09:00 Parathyroid gland in Health °­µ¿Çõ(ºÎõ ¼º¸ðº´¿ø)

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 09:00~09:20 Parathyroid cell proliferation in Disease; Primary vs. Secondary Á¤°æõ(¼­¿ï´ëº´¿ø º´¸®°ú)

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 09:20~09:50 Consequences of Hyperparathyroidism - mineral, bone, extra skeletal Á¤Áö¿ë(°¡Ãµ±æº´¿ø)

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 09:50~10:20 Differential diagnosis in Primary hyperparathyroidism in CKD Á¶¾ÆÁø(ÇѸ²´ë °­³²¼º½Éº´¿ø)

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 10:20~10:50 Imaging for Hyperparathyroidism; Primary vs. Secondary ÃÖÇýÁ¤(ºÐ´çÂ÷º´¿ø ¿µ»óÀÇÇаú )

ÈÞ½Ä 09¿ù 10ÀÏ ´ë°­´ç 10:50~11:10 Break ()

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 11:10~11:35 Additive beneficial effects of GLP-1 agonist in CKD [IV & oral] ±èÁ°æ(ÆòÃÌ ÇѸ²´ëº´¿ø)

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 11:35~12:00 Additive beneficial effects of mineralocorticoid receptor antagonist in CKD ÃÖÀ¯Á¤(°í´ë±¸·Îº´¿ø ¼øȯ±â)

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 12:00~12:20 Primary hyperparathyroidism Guideline 2022 È«¾Æ¶÷(È­¼øÀü³²ÀÇ´ë)

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 12:20~12:50 Surgery vs. Radiofrequency Ablation ±è¿ì¿µ(°í´ë±¸·Îº´¿ø)

±³À°½Ã°£ 09¿ù 10ÀÏ ´ë°­´ç 12:50~13:30 VDRAs, Cinacalcet, Evocalcet, Etelcalcetide & Upacicalcet in Secondary hyperparathyroidism ¾È½Å¿µ(°í´ë±¸·Îº´¿ø)

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­Á : 2024-03-09

±³À°ÀÏÀÚ : 2024-03-09 ±³À°Àå¼Ò : (¿Â¶óÀÎ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,657 , ´ñ±Û¼ö : 0

[¼­¿ï] Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialysis Vascular Access) : 2024-03-31

±³À°ÀÏÀÚ : 2024-03-31 ±³À°Àå¼Ò : °¡Å縯ÀÇ´ë ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ ±³À°ÁÖÁ¦ : Á¦26Â÷ °¡Å縯ÀÇ´ë ½ÅÀå³»°ú ¿¬¼ö±³À° (Clinical Topics on Hemodialy

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,712 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,708 , ´ñ±Û¼ö : 0

[¼­¿ï] ¼¼ºê¶õ½ºº´¿ø 2018 ¼¼¸ñȸ Çмú´ëȸ : 2018-11-10

±³À°ÀÏÀÚ : 2018-11-10 ±³À°Àå¼Ò : °­³² ¼¼ºê¶õ½ºº´¿ø ´ë°­´ç ±³À°ÁÖÁ¦ : 2018 ¼¼¸ñȸ Çмú´ëȸ ÁÖÃÖ±â°ü : ¼¼ºê¶õ½ºº´¿ø ½ÃÇà±â°ü(ÁöºÎ/°ú) : ¾È°ú ´ã´çÀÚ : ¹Ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 6,392 , ´ñ±Û¼ö : 0

[¼­¿ï] ´ëÇÑÁ¶Çöº´ÇÐȸ Treatment and management of symptoms and physical health in schizophrenia : 2024-04-2..

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü ±³À°ÁÖÁ¦ : Treatment and management of symptoms and physical health i

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,398 , ´ñ±Û¼ö : 0